Introduction
Cervical cancer begins when cells of the cervix—the lower part of the uterus that opens into the vagina—grow abnormally and invade nearby tissues. Most cases are linked to persistent infection with high-risk types of human papillomavirus (HPV), especially HPV 16 and 18.
The disease usually develops slowly over years, often passing through precancerous stages (CIN) that screening can detect and treat before cancer forms. Early disease may cause no symptoms, which is why Pap and HPV testing matter.
When symptoms appear, they may include bleeding between periods or after sex, unusual discharge, or pelvic pain. Treatment depends on stage and may include surgery, chemoradiation, systemic therapy, or a combination.
HPV vaccination plus regular screening have sharply reduced cervical cancer in regions where both are widely used. This page is general education; screening intervals and treatment choices should follow your clinician and local guidelines.
Overview
Most cervical cancers are squamous cell carcinomas arising on the outer cervix; adenocarcinomas arise from glandular cells of the cervical canal and can be harder to catch with cytology alone.
Staging (commonly FIGO) describes tumor size, local spread, lymph nodes, and distant metastasis, and guides whether surgery, radiation, or systemic therapy is primary.
Prevention rests on three pillars: HPV vaccination, age-appropriate screening, and timely treatment of high-grade precancer.
- Usually driven by persistent high-risk HPV infection
- Often preceded by treatable precancer (CIN)
- Main types: squamous cell carcinoma and adenocarcinoma
- Early disease is frequently asymptomatic—screening is essential
- Treatment is stage-based: surgery, chemoradiation, systemic therapy
- Vaccination and screening prevent most cases
What happens in the body
High-risk HPV can integrate into cervical cell DNA and disrupt growth control. Over years, dysplasia may progress from low-grade to high-grade lesions and then invasive cancer if untreated.
Immune clearance eliminates most HPV infections; persistence is more likely with smoking, HIV or other immunosuppression, and lack of screening follow-up.
- Persistent high-risk HPV causes most cervical cancers
- Progression from precancer to invasion usually takes years
- Smoking and immunosuppression favor persistence and progression
- Screening interrupts the pathway by finding and treating CIN
Signs and symptoms
Early cervical cancer often has no warning signs. When symptoms occur, common ones include:
- Bleeding between periods, after intercourse, or after menopause
- Heavier or longer menstrual bleeding than usual
- Watery, bloody, or foul-smelling vaginal discharge
- Pain during sex
- Pelvic or lower back pain in more advanced disease
- Painful urination or blood in urine when local spread involves the bladder pathway
- Leg swelling if lymphatic drainage is blocked
- Fatigue, weight loss, or reduced appetite in advanced stages
Causes and risk factors
Persistent high-risk HPV is the dominant cause. Additional risk factors include:
- Persistent infection with high-risk HPV types (especially 16 and 18)
- Missing regular Pap/HPV screening
- Smoking or heavy secondhand smoke exposure
- Weakened immunity (HIV, transplant medicines, long-term steroids)
- Early sexual debut or multiple partners (increased HPV exposure probability—not moral judgment)
- History of other sexually transmitted infections
- Long-term combined oral contraceptive use (small added risk; weigh with clinician)
- Rare in utero DES exposure in past generations
- HPV spreads by intimate skin contact; having HPV is common and not a personal failure
Diagnosis and evaluation
Screening finds risk; biopsy confirms disease. Evaluation typically includes:
- Pap test and/or HPV test at recommended ages and intervals
- Colposcopy with targeted biopsy after abnormal screening or suspicious symptoms
- Endocervical sampling when the canal needs assessment
- Excisional procedures (LEEP or cone) that can diagnose and treat high-grade precancer
- Pelvic MRI for local staging once cancer is confirmed
- CT or PET-CT for nodes and distant spread as indicated
- Blood counts, kidney/liver tests, and pregnancy test when relevant
- FIGO staging to plan surgery versus chemoradiation versus systemic therapy
Treatment and management
Plans are individualized by stage, fertility goals, and overall health. Do not stop cancer therapy without oncology advice:
- LEEP or cold-knife cone for high-grade precancer or selected microinvasive disease
- Fertility-sparing surgery in carefully chosen very early cancers
- Simple or radical hysterectomy with lymph-node assessment for appropriate early stages
- Pelvic chemoradiation (external beam plus brachytherapy, often with cisplatin) for many locally advanced cancers
- Neoadjuvant or adjuvant chemotherapy based on pathology and risk
- Bevacizumab, immunotherapy, or other systemic options in selected recurrent/metastatic disease
- Supportive care: antiemetics, pain control, nutrition, sexual health, and psychosocial support
- Fertility counseling before treatment whenever pregnancy is a future goal
Prevention, self-care, and lifestyle
Not every condition is fully preventable, but the steps below may lower risk or recurrence:
- HPV vaccination for eligible adolescents and catch-up age groups per guidelines
- Regular cervical screening and follow-up of abnormal results
- Prompt treatment of CIN2/3 to prevent invasion
- Condoms reduce but do not eliminate HPV transmission—vaccination and screening remain key
- Stop smoking to improve cervical health and treatment outcomes
- Balanced diet, sleep, and HIV care when applicable to support immune clearance
Possible complications
Delay, missed care, or unsafe self-medication can raise the chance of complications in some cases:
- Local invasion of vagina, parametria, bladder, or rectum
- Lymph-node and distant metastasis
- Treatment-related effects: infertility, menopause symptoms, vaginal stenosis, bowel/bladder changes
- Lymphedema after node surgery or radiation
- Recurrence if follow-up is missed
- Emotional distress, sexual health challenges, and financial strain during care
When to see a doctor or seek emergency care
Seek prompt medical advice or emergency care if any of the following apply—it is safer not to wait and see:
- Any postmenopausal bleeding
- Bleeding after sex or between periods that is new for you
- Persistent unusual vaginal discharge
- Pelvic pain with bleeding or discharge
- Missed screening for years—book a catch-up visit
- Urgent care for heavy bleeding, severe pain, or fainting
Living with the condition
After treatment, surveillance visits look for recurrence and help manage side effects. Report new bleeding, pain, or swelling promptly.
Sexual health, vaginal moisturizers or dilators after radiation, pelvic-floor therapy, and counseling can restore comfort for many people—ask early rather than suffering silently.
Survivorship also includes bone, heart, and metabolic health after cancer therapy, plus emotional support for anxiety about recurrence.
Frequently asked questions
What causes cervical cancer?
Most cases follow persistent high-risk HPV infection. Screening and vaccination greatly reduce risk.
Does early cervical cancer have symptoms?
Often no. That is why Pap/HPV screening is recommended even when you feel well.
Can cervical cancer be prevented?
Yes—HPV vaccination, regular screening, and treatment of precancer prevent most cases.
How is it treated?
Depending on stage: excision or hysterectomy for early disease; chemoradiation for many locally advanced cancers; systemic therapy for advanced or recurrent disease.
Is HPV the same as cervical cancer?
No. HPV is very common and usually clears. Only persistent high-risk infection plus other factors lead to precancer or cancer over time.
Important caution
This article is general health education in English. It is not personal medical advice, a screening schedule tailored to you, or a treatment prescription.
Decisions about vaccination, tests, surgery, or chemoradiation should follow a qualified clinician.
Seek care promptly for abnormal bleeding, and do not delay recommended screening.